David Lebowitz
Stock Analyst at Citigroup
(0)
# 3704
Out of 5,291 analysts
112
Total ratings
45.45%
Success rate
-1.22%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Pliant Therapeutics | Maintains: Neutral | 4 2 | 1.47 | 2.04% | 6 | Mar 4, 2025 | |
Intellia Therapeutic... | Maintains: Neutral | 12 14 | 8.06 | 73.7% | 7 | Feb 28, 2025 | |
BridgeBio Pharma | Maintains: Strong Buy | 45 49 | 35.11 | 39.56% | 3 | Feb 21, 2025 | |
Ionis Pharmaceutical... | Maintains: Buy | 67 64 | 31.12 | 105.66% | 12 | Feb 20, 2025 | |
Exelixis | Maintains: Strong Buy | 38 45 | 36.7 | 22.62% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 32 45 | 54.18 | -16.94% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 97 88 | 60.59 | 45.24% | 5 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 38 | 25.61 | 48.38% | 1 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 86 | 43.2 | 99.07% | 1 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 65 68 | 45.99 | 47.86% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 70 | 19.92 | 251.41% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 13 15 | 6.45 | 132.56% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 178 207 | 154.59 | 33.9% | 12 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 65 76 | 88.69 | -14.31% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 39 37 | 19.98 | 85.19% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 382 | 327.91 | 16.5% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 103 96 | 71.4 | 34.45% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 18 12 | 1.65 | 627.27% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 170 164 | 268.5 | -38.92% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 36 39 | 15.73 | 147.93% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 21 | 13.17 | 59.45% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 435 405 | 4.2 | 9542.86% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 13 14 | 1.42 | 885.92% | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 324 300 | n/a | n/a | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 10 5 | n/a | n/a | 2 | Aug 10, 2021 |